beta-lactam antimicrobial + metronidazole

This investigational antimicrobial regimen consists of an intravenous beta-lactam antibiotic combined with metronidazole, specifically studied by the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, for the treatment of uncomplicated liver abscess. The beta-lactam component typically includes broad-spectrum agents such as piperacillin-tazobactam, ceftriaxone, meropenem, or imipenem-cilastatin. Beta-lactams function by inhibiting bacterial cell wall synthesis through the binding of penicillin-binding proteins (PBPs), while metronidazole targets anaerobic bacteria and Entamoeba histolytica by disrupting DNA synthesis through the formation of cytotoxic intermediate radicals. This combination provides comprehensive coverage against enteric gram-negative bacilli, streptococci, and anaerobes, which are common causative agents of pyogenic and amoebic liver abscesses.

Other names

intravenous beta-lactam antimicrobial plus metronidazoleIV beta-lactam + metronidazole